Literature DB >> 19701949

Triclosan inhibit the growth of the late liver-stage of Plasmodium.

Agam Prasad Singh1, Namita Surolia, Avadhesha Surolia.   

Abstract

Annually, approximately two million human deaths are caused worldwide by malaria, most of them being children. Plasmodium falciparum is the leading cause of cerebral malaria, the most severe and fatal form of disease. Moreover, the emergence of resistant strains to the existing drugs has worsened the situation. Currently, primaquine is the only drug available for eliminating liver-stage parasites. Because of the emergence of resistant parasite strains, it becomes necessary to find new targets unique to the malaria parasites. In the Plasmodium species, the discovery of a distinct Type-II fatty-acid synthesis pathway has created an opportunity to target this pathway for the development of new inhibitors of malaria parasite growth. The present study explored the growth inhibition potential of triclosan in the case of liver-stage parasites. Liver-stage of Plasmodium is an excellent target for intervention due to very small parasite load as well as possibility of eliminating parasites before it can cause blood-stage infection. Here we report that triclosan inhibits the development of the Plasmodium liver-stage parasites. (c) 2009 IUBMB

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19701949     DOI: 10.1002/iub.237

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  7 in total

1.  Potential of lichen secondary metabolites against Plasmodium liver stage parasites with FAS-II as the potential target.

Authors:  Ina L Lauinger; Livia Vivas; Remo Perozzo; Christopher Stairiker; Alice Tarun; Mire Zloh; Xujie Zhang; Hua Xu; Peter J Tonge; Scott G Franzblau; Duc-Hung Pham; Camila V Esguerra; Alexander D Crawford; Louis Maes; Deniz Tasdemir
Journal:  J Nat Prod       Date:  2013-06-19       Impact factor: 4.050

2.  Trypanosoma brucei: inhibition of acetyl-CoA carboxylase by haloxyfop.

Authors:  Patrick A Vigueira; Kimberly S Paul
Journal:  Exp Parasitol       Date:  2011-11-19       Impact factor: 2.011

3.  Dual-resolution molecular dynamics simulation of antimicrobials in biomembranes.

Authors:  Mario Orsi; Massimo G Noro; Jonathan W Essex
Journal:  J R Soc Interface       Date:  2010-12-03       Impact factor: 4.118

4.  2-Hexadecynoic acid inhibits plasmodial FAS-II enzymes and arrests erythrocytic and liver stage Plasmodium infections.

Authors:  Deniz Tasdemir; David Sanabria; Ina L Lauinger; Alice Tarun; Rob Herman; Remo Perozzo; Mire Zloh; Stefan H Kappe; Reto Brun; Néstor M Carballeira
Journal:  Bioorg Med Chem       Date:  2010-09-18       Impact factor: 3.641

Review 5.  Peroxisome proliferator activating receptor (PPAR) in cerebral malaria (CM): a novel target for an additional therapy.

Authors:  S Balachandar; A Katyal
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-12-09       Impact factor: 3.267

6.  Assessment of dual life stage antiplasmodial activity of british seaweeds.

Authors:  Jasmine Spavieri; Andrea Allmendinger; Marcel Kaiser; Maurice Ayamba Itoe; Gerald Blunden; Maria M Mota; Deniz Tasdemir
Journal:  Mar Drugs       Date:  2013-10-22       Impact factor: 5.118

7.  Plasmodium dihydrofolate reductase is a second enzyme target for the antimalarial action of triclosan.

Authors:  Elizabeth Bilsland; Liisa van Vliet; Kevin Williams; Jack Feltham; Marta P Carrasco; Wesley L Fotoran; Eliana F G Cubillos; Gerhard Wunderlich; Morten Grøtli; Florian Hollfelder; Victoria Jackson; Ross D King; Stephen G Oliver
Journal:  Sci Rep       Date:  2018-01-18       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.